Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 14 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from very attractive to attractive, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 14, an EV to EBITDA of 11.16, and a PEG ratio of 0.39, suggesting that the stock is reasonably priced relative to its growth prospects.
In comparison to its peers, GE Healthcare Technologies has a lower P/E ratio than Edwards Lifesciences Corp. at 31.17 and Agilent Technologies, Inc. at 27.42, indicating it may be undervalued relative to these companies. The company's recent performance shows a year-to-date return of -6.43%, while the S&P 500 has returned 14.49%, reinforcing the notion that the stock may be underperforming the broader market.